A man waves a Colorado flag with a marijuana leaf on it at Denver’s annual 4/20 marijuana rally in front of the state capitol building in downtown Denver, April 20, 2015. (photo: Rick Wilking/Reuters)
Christopher Woody | International Business Times | Reader Supported News | May 18, 2016
n April, the US Drug Enforcement Administration (DEA) said it would review marijuana’s classification as a Schedule I drug, considered the “most dangerous class” of substances.
While the DEA’s announcement is a positive sign, many drug policy experts think it’s unlikely the agency will actually decide to change marijuana’s classification, despite a dramatic shift in public sentiment about the drug.
Marijuana’s position in the top tier of the scheduling system — which organizes drugs by their “acceptable medical use and … abuse or dependency potential” — has endured since the 1970s.
“DEA will carry out its assessment of the FDA recommendation in accordance with the [Controlled Substances Act] … and hopes to release its determination in the first half of 2016,” the DEA said in a letter to a group of Democratic senators, first obtained by the Huffington Post.